- Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised.1-3
- Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample.
- Flexible syndromic testing tailored to patient needs reduces unnecessary testing and provides clinicians with actionable insights sooner when compared to conventional methods.
- This flexible solution will enable Roche to provide a broad range of respiratory targets with up to three tests out of one sample and can be combined with our COVID-19 offering on cobas® 6800/8800 Systems.
Roche today announced the launch of three molecular PCR diagnostic assay panels to simultaneously detect and differentiate common respiratory pathogens:
influenza A, influenza B and respiratory syncytial virus (RSV)
adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV)
parainfluenza 1, 2, 3 and 4
The three tests are often run together or individually from one nasopharyngeal swab specimen. As respiratory viruses circulating within a community can vary counting on seasonality and geography, a versatile testing option supported a syndromic-style panel enables personalised healthcare and helps reduce unnecessary testing.
Patients with respiratory infections often have signs and symptoms that are indicative of the disease, but aren’t specific enough to discern the basis explanation for the illness. Syndromic testing allows clinicians to check patients simultaneously for multiple pathogens supported overlapping symptoms. By detecting the foremost common pathogens that cause disease on a versatile set of test panels together, clinicians are given actionable insights therefore the right therapeutic are often prescribed sooner compared to standard test methods. This successively enables timely infection control, proper single bed management and improved patient care.
“Our latest set of syndromic respiratory solutions allows clinicians to settle on the acceptable tests supported the healthcare setting, season and patient needs,” said Thomas Schinecker, CEO Roche Diagnostics. ”By testing only what’s medically relevant and necessary, we enable targeted therapy, avoid misuse of antibiotics and reduce unnecessary intervention.”
These new respiratory test panels run on the cobas omni Utility Channel to be used with the widely available, high-volume cobas® 6800/8800 Systems, which have proven to bring reliable results quickly to satisfy the urgent demand for patient testing during the COVID-19 pandemic. Addition of those tests will equip health systems to combat new respiratory diseases once they arise. Roche is looking to expand availability of those tests beyond CE markets within the future.
About respiratory infections
Acute respiratory infections are one among the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and therefore the immnocompromised.1-3 tract infections include both upper tract infections, just like the cold , and lower tract infections, like pneumonia, bronchitis and tuberculosis. Respiratory infections are caused by a good sort of pathogens, like influenza viruses, respiratory syncytial virus, parainfluenza viruses, metapneumovirus, rhinovirus, enterovirus, coronavirus and adenovirus, and other bacteria pathogens.
About the three new Roche tests for Influenza A/B, RSV; ADV, hMPV, EV/RV; and Parainfluenza 1-4
These tests utilise a real-time PCR macromolecule amplification method to detect specific DNA sequences obtained after extraction or following reverse transcription of RNA. TaqMan® DNA probes that hybridise with the target strand are labeled with a fluorescein allowing real-time measurements during the PCR process. Real-time PCR technology allows a rapid and specific measurement of the presence of genes from microorganisms related to infectious diseases, cancer, and genetic abnormalities.
About the cobas omni Utility Channel on the cobas 6800/8800 Systems
The cobas omni Utility Channel on the cobas 6800/8800 Systems enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on one platform. Open channel assays may include IVD assays, also as routine lab developed tests (LDTs). the power to consolidate and automate a wider array of testing on one platform helps to extend operational efficiency, maximise laboratory space and minimise capital investment.
The fully automated cobas 6800/8800 Systems offer the fastest time to results with the very best throughput and therefore the longest walk-away time available among automated molecular platforms. With proven performance, absolute automation and unmatched flexibility delivering unparalleled throughput 24/7—cobas 6800/8800 Systems are designed to make sure a lab’s long-term sustainability and success.
Roche may be a global pioneer in pharmaceuticals and diagnostics focused on advancing science to enhance people’s lives. The combined strengths of pharmaceuticals and diagnostics, also as growing capabilities within the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is functioning with partners across the healthcare sector to supply the simplest look after everyone .
Roche is that the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central systema nervosum . Roche is additionally the planet leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Source link: https://www.roche.com/